Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Savara, Inc. - Common Stock (NQ:SVRA)

5.250 -0.030 (-0.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,271,775
Open 5.190
Bid (Size) 4.950 (1,000)
Ask (Size) 6.010 (1,500)
Prev. Close 5.280
Today's Range 5.140 - 5.340
52wk Range 1.890 - 7.005
Shares Outstanding 114,066,080
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
VR Adviser Adds Over 1 Million Savara Shares ↗
This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire

Performance

YTD
-6.9%
-6.9%
1 Month
-6.9%
-6.9%
3 Month
-18.6%
-18.6%
6 Month
+51.3%
+51.3%
1 Year
+94.4%
+94.4%

More News

Read More
News headline image
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in 2026 Citizens Life Sciences Conference
From Savara Inc.
Via Business Wire
News headline image
SVRA Stock Rises After Hours As FDA Grants Priority Review For Lung Disorder Therapy ↗
Via Stocktwits
Topics Intellectual Property Lawsuit
Get insights into the top gainers and losers of Friday's after-hours session. ↗
Via Chartmill
News headline image
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in Upcoming Investor Healthcare Conferences
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
From Savara Inc.
Via Business Wire
News headline image
SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
News headline image
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
From Savara Inc.
Via Business Wire
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
From Savara Inc.
Via Business Wire
News headline image
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
From Savara Inc.
Via Business Wire
News headline image
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in Upcoming Investor Healthcare Conferences
From Savara Inc.
Via Business Wire
News headline image
Savara Reports Third Quarter 2025 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
News headline image
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Class Action Filed Against Savara Inc. (SVRA) - November 7, 2025 Deadline to Join - Contact Levi & Korsinsky
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Class Action Filed Against Savara Inc. (SVRA) - November 7, 2025 Deadline to Join - Contact Levi & Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Deadline Soon: Savara Inc. (SVRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
SAVARA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Savara Stockholders to Contact the Firm Before November 7th
From Bragar Eagel & Squire
Via GlobeNewswire

Frequently Asked Questions

Is Savara, Inc. - Common Stock publicly traded?
Yes, Savara, Inc. - Common Stock is publicly traded.
What exchange does Savara, Inc. - Common Stock trade on?
Savara, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Savara, Inc. - Common Stock?
The ticker symbol for Savara, Inc. - Common Stock is SVRA on the Nasdaq Stock Market
What is the current price of Savara, Inc. - Common Stock?
The current price of Savara, Inc. - Common Stock is 5.250
When was Savara, Inc. - Common Stock last traded?
The last trade of Savara, Inc. - Common Stock was at 03/26/26 04:00 PM ET
What is the market capitalization of Savara, Inc. - Common Stock?
The market capitalization of Savara, Inc. - Common Stock is 598.85M
How many shares of Savara, Inc. - Common Stock are outstanding?
Savara, Inc. - Common Stock has 599M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.